Table of Contents
Executive Summary — 6
SWOT
Analysis — 7
Hungary Pharmaceuticals And Healthcare
Industry SWOT — 7
Hungary Political
SWOT — 8
Hungary Economic SWOT — 9
Hungary Business Environment SWOT — 10
Pharmaceuticals &
Healthcare Business Environment — 11
Table: Central And
Eastern Europe Pharmaceuticals Business Environment Ratings For
Q309 — 11
Limits to Potential
Returns — 12
Risks to Realisation of
Returns — 12
Hungary – Market
Summary — 13
Regulatory Regime — 14
Recent EU Regulatory Developments — 15
Intellectual
Property Regime — 16
Pricing
Regime — 17
Table: Hungary – Pharmaceutical Price
Build-Up — 18
Table: Hungary – Average Pharmacy
Mark-Up — 19
Reimbursement Regime — 20
Price Cuts — 21
Pricing and Reimbursement
Reforms — 22
Industry
Developments — 24
Epidemiology — 24
Healthcare Financing — 24
Healthcare
Reforms — 25
Hospital Sector
Reforms — 27
Research and
Development — 28
Table: Special Incentive Package For
Investors Willing To Establish An R&D Facility Worth At Least EUR10mn in
Hungary — 29
Biotechnology Sector — 30
Medical Devices — 31
Industry Forecast
Scenario — 32
Overall Market
Forecast — 32
Table: Hungary’s Drug Market Forecast,
2004-2013 — 33
Key Growth Factors –
Industry — 34
Table: Hungary’s Health Expenditure
Indicators, 2004-2013 — 35
Key Growth Factors –
Macroeconomic — 36
Economic
Activity — 36
Table: Hungary - Economic Activity,
2005-2013 — 39
Prescription Market
Forecast — 40
Table: Hungary’s Prescription Market
Indicators, 2004-2013 (HUFmn unless otherwise)
stated) — 41
OTC Market Forecast — 42
Table: Hungary’s OTC Market Indicators, 2004-2013 (HUFmn unless
otherwise) stated) — 43
Patented Market
Forecast — 44
Table: Hungary’s Patented Drug Market
Indicators, 2004-2013 — 45
Generics Market
Forecast — 46
Table: Hungary’s Generics Market
Indicator Forecasts, 2004-2013 — 46
Export/Import
Forecasts — 47
Table: Hungary’s Import/Export Market
Forecasts, 2004-2013 (US$mn) — 48
Medical Devices
Forecast — 49
Table: Hungary’s Medical Device Market
2004-2013 — 50
Other Healthcare Data
Forecasts — 51
Table: Hungary’s Other Healthcare
Data, 2004-2013 — 51
Key Risks to BMI’s Forecast
Scenario — 51
Competitive
Landscape — 52
Table: Leading Pharmaceutical Companies By
Ownership — 53
Domestic Price Cuts Calculated For Total
Egis Portfolio — 56
Wholesale and Retail Pharmacy
Sector — 58
Company Monitor — 60
Multinational Companies — 60
Pfizer — 60
Novartis — 62
Sanofi-Aventis — 63
GlaxoSmithKline — 65
Merck & Co — 66
Eli Lilly — 67
Krka — 69
Domestic
Manufacturers — 71
Gedeon Richter — 71
Egis Pharmaceuticals (Servier) — 75
Country Snapshot:
Hungary Demographic Data — 78
Section 1:
Population — 78
Table: Demographic Indicators,
2005-2030 — 78
Table: Rural/Urban Breakdown,
2005-2030 — 79
Section 2: Education and
Healthcare — 79
Table: Education,
2002-2005 — 79
Table: Vital Statistics,
2005-2030 — 79
Section 3: Labour Market and Spending
Power — 80
Table: Employment Indicators,
2001-2006 — 80
Table: Consumer Expenditure, 2000-2012
(US$) — 81
Table: Average Annual Wages,
2000-2012 — 81
BMI Forecast
Modelling — 82
How We Generate Our Pharmaceutical Industry
Forecasts — 82
Pharmaceutical Business Environment Ratings
Methodology — 83
Ratings Overview — 83
Table: Pharmaceutical Business Environment Indicators — 84
Weighting — 85
Table: Weighting Of
Components — 85
Sources — 85
| 
View Cart
